[Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis].

Xu, Y; Pan, R L; Huang, H; Wang, M Z

Xu, Y; Pan, R L; Huang, H; Wang, M Z.

Afiliação

Xu Y; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Pan RL; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Huang H; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Wang MZ; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Zhonghua Yu Fang Yi Xue Za Zhi ; 57(8): 1176-1180, 2023 Aug 06.

Article em Zh | MEDLINE | ID: mdl-37574309

Assuntos

Neoplasias Pulmonares; Pneumonia; Humanos; Inibidores de Checkpoint Imunológico/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Neoplasias Pulmonares Tipo de estudo: Screening_studies Limite: Humans Idioma: Zh Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google